MDT

99.08

-0.7%↓

A

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

A

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

A

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

A

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

A

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

Search

Ionis Pharmaceuticals Inc

Abierto

SectorSalud

80.61 -3.26

Resumen

Variación precio

24h

Actual

Mínimo

80.57

Máximo

84.99

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+10.71% upside

Dividendos

By Dow Jones

Próximas Ganancias

18 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

13B

Apertura anterior

83.87

Cierre anterior

80.61

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

166 / 372 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ene 2026, 23:11 UTC

Ganancias

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 ene 2026, 22:55 UTC

Principales Movimientos del Mercado

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 ene 2026, 21:39 UTC

Principales Movimientos del Mercado

Raytheon Down Following Trump Post Criticizing Company

7 ene 2026, 20:13 UTC

Principales Movimientos del Mercado

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 ene 2026, 20:03 UTC

Principales Movimientos del Mercado

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 ene 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 ene 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 ene 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 ene 2026, 23:29 UTC

Adquisiciones, fusiones, absorciones

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 ene 2026, 22:48 UTC

Charlas de Mercado

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 ene 2026, 22:46 UTC

Ganancias

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 ene 2026, 22:42 UTC

Ganancias

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 ene 2026, 22:41 UTC

Ganancias

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 ene 2026, 22:41 UTC

Ganancias

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 ene 2026, 22:40 UTC

Principales Movimientos del Mercado

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 ene 2026, 22:31 UTC

Charlas de Mercado

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 ene 2026, 22:22 UTC

Charlas de Mercado

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 ene 2026, 22:01 UTC

Charlas de Mercado

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 ene 2026, 21:46 UTC

Charlas de Mercado

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 ene 2026, 21:22 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 ene 2026, 21:18 UTC

Adquisiciones, fusiones, absorciones

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 ene 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 ene 2026, 20:29 UTC

Adquisiciones, fusiones, absorciones

AbbVie Near Deal for Revolution Medicines -- Update

7 ene 2026, 20:27 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 ene 2026, 19:58 UTC

Charlas de Mercado

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 ene 2026, 19:48 UTC

Principales Movimientos del Mercado

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

10.71% repunte

Estimación a 12 meses

Media 92.08 USD  10.71%

Máximo 110 USD

Mínimo 65 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

14

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

166 / 372 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat